About LYFE Capital
LYFE Capital is a venture capital firm founded in 2015. It is primarily based out of Menlo Park, United States. As of Nov 2025, LYFE Capital has invested in 42 companies. It primarily invests in Series B round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series C round of Aspen Neuroscience Overall, LYFE Capital portfolio has seen 1 unicorn, 9 IPOs and 2 acquisitions including key companies like Cytek Biosciences, Burning Rock and Neurona Therapeutics. A lot of funds co-invest with LYFE Capital, with names like Hillhouse sharing a substantial percentage of its portfolio. LYFE Capital has team of 28 people including 12 partners.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
Portfolio Soonicorns
Deals in last 12 months
LYFE Capital's List of Top Investments
LYFE Capital has a portfolio of 42 companies, one of which is a Unicorn. Their most notable investments are in Shenzhen Jingfeng Medical Technology and Magair Chemical.Their portfolio spans across China, United States, France and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Series B, Series A and 4 more. Here is the list of top investments by LYFE Capital:Manufacturer of flow cytometry systems for research applications. The company's flagship product is the DxP Athena flow cytometer which can be configured for detection of colors with lasers. The systems can also be equipped with liquid handling components for automatic micro-sampling, and fluid management system.
Key facts about Cytek Biosciences
- Founded Year: 2014
- Location: San Francisco (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $144M
- Employee Count: 445 as on May 31, 2026
- Investors: HTIF, Orbimed and 12 Others
- Latest Funding Round: Series D, Nov 05, 2020, $*****
- Highlight: Public
2. Burning Rock
Developer of personalized diagnostic and treatment services based on genomic big data analysis. It provides next-generation sequencing-based cancer diagnostics, including bioinformatics analysis and tumor molecular pathology, and immunohistochemistry. Uses diagnostic tools to gather the information that enables the personalized treatment of cancer. It also offers liquid biopsy tests for lung cancer.
Key facts about Burning Rock
Provider of genomic-based personalized pluripotent stem cell therapy. It offers regenerative cell treatment like dopaminergic neurons for Parkinson's disease and other neurological disorders. It maintains the genetic-based quality control to avoid the mutation of cells used for therapy.
Key facts about Aspen Neuroscience
- Founded Year: 2018
- Location: San Diego (United States)
- Stage: Series C
- Total Funding till date: $339M
- Employee Count: 127 as on May 31, 2026
- Investors: Timefolio Capital, EDBI and 22 Others
- Latest Funding Round: Series C, Nov 20, 2025, $*****
- Highlight: Editors' Pick
Developer of cell-based therapies to treat intractable neurological diseases. It generate therapeutic compositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. It offers NRTX-1001, an inhibitory neuron therapy for epilepsy by GABAergic inhibition, reduce seizure activity, and repair the affected neural network.
Key facts about Neurona Therapeutics
- Founded Year: 2008
- Location: San Francisco (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $418M
- Employee Count: 112 as on May 31, 2026
- Investors: Fidelity Investments, Topspin Fund and 15 Others
- Latest Funding Round: Series E, Mar 28, 2025, $*****
- Highlight: Acquired
Developer of T-cell therapy for autoimmune disease. The therapeutic platform combines T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells of inflammatory diseases.
Key facts about Kyverna Therapeutics
- Founded Year: 2018
- Location: Berkeley (United States)
- Stage: Public
- Total Funding till date: $322M
- Employee Count: 157 as on May 31, 2026
- Investors: RTW Investments, Bain Capital Life Sciences and 13 Others
- Latest Funding Round: Series B, Aug 03, 2023, $*****
- Highlight: Public
LYFE Capital's Year-on-Year Investment Trends
LYFE Capital has invested in 43 companies over the last 11 years, with an average of 4 new investments annually in the last 10 years. In 2025, it made 3 investments. Its most recent first time investment was in Verdiva Bio and most recent follow-on round was in Aspen Neuroscience.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 2 | 3 |
2024 | 3 | 1 | 4 |
2023 | 1 | 2 | 3 |
2022 | 8 | 4 | 12 |
2021 | 12 | 4 | 16 |
2020 | 7 | 0 | 7 |
2019 | 0 | 3 | 3 |
2018 | 7 | 0 | 7 |
LYFE Capital's Investments by Stage
LYFE Capital has made 16 investments in Series B stage with an average round size of $71M, 15 investments in Series A stage with an average round size of $67.1M and 3 investments in Series C stage with an average round size of $54.1M.Stage of entry | No. of Investments |
|---|---|
Series B | 16 |
Series A | 15 |
Series C | 3 |
Series D | 3 |
Series E | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
LYFE Capital's Investments by Sector
LYFE Capital has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, Sustainability Tech and HealthTech. Notably, it has invested in 34 Enterprise (B2B) companies, 32 Tech companies, 8 Tech hardware companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 32 |
High Tech | 11 |
Healthcare | 6 |
Sustainability Tech | 4 |
HealthTech | 2 |
Others | 5 |
Note: We have considered here, only first round of investments
LYFE Capital's Investments by Geography
LYFE Capital has made most investments in China (23), followed by United States where it has made 13 investments.Country | No. of Investments |
|---|---|
China | 23 |
United States | 13 |
France | 1 |
Israel | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
LYFE Capital's recent investments
LYFE Capital has not made any investment in 2026 so far.Here are the most recent investments by LYFE Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Nov 20, 2025 | United States | Series C | 2366 | [+11] | |
Oct 22, 2025 | China | Series B | 5742 | [+4] | |
Jan 09, 2025 | United Kingdom | Series A | 6670 | [+5] | |
Feb 13, 2024 | United States | Series B | 2661 | [+12] | |
Feb 06, 2024 | United States | Series E | 4646 | [+10] |
Unicorns in LYFE Capital's Portfolio
LYFE Capital has 1 unicorn in its portfolio - Abogen Biosciences. The most recent unicorn in their portfolio is Abogen Biosciences which became a unicorn in 2021.Here is a list of unicorns in LYFE Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
42 | Developer of mRNA-based therapeutics for cancer and infectious diseases | 2019 | Suzhou | Series C | o{kyxod |
IPOs and Publicly Listed companies in LYFE Capital's Portfolio
9 of LYFE Capital's portfolio companies have become public. Shenzhen Jingfeng Medical Technology got listed on the Hong Kong Exchanges (HKG), in Jan 2026 at marketcap of $2.15B and Kyverna Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $898M.Here are LYFE Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jan 08, 2026 | Jan 22, 2021 | Series B | 5134 | |
Feb 08, 2024 | Jan 26, 2022 | Series B | 2437 | |
Sep 05, 2023 | Oct 12, 2020 | Series B | 3689 | |
Mar 31, 2022 | Dec 17, 2020 | Series B | 3982 | |
Dec 10, 2021 | Dec 01, 2020 | Series E | 5454 |
Acquired companies in LYFE Capital's Portfolio
2 companies from LYFE Capital's portfolio have been acquired. The most recent acquisition was Neurona Therapeutics in Apr 2026 by UCB for $*****.Here are LYFE Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 21, 2026 | Feb 06, 2024 | Series E | 2953 | |
Apr 03, 2024 | Jul 12, 2021 | Series A | 4973 |
Team profile of LYFE Capital
LYFE Capital has a team of 28 members including 12 Partners and 7 Principals located in China, United States and 2 more locations. LYFE Capital's team does not sit on the board of any company as of now.Here is a list of top team members in LYFE Capital:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Shanghai | - | - | |
Partner | Pudong | - | - | |
Partner | Del Mar | - | - | |
Partner | Shanghai | - | - | |
Partner | Menlo Park | - | - | |
Partner | Jing'an | - | - | |
Partner | Shanghai | - | - | |
Partner | Jing'an | - | - | |
Partner | New York City | - | - | |
Partner | Singapore | - | - |
Co-investors of LYFE Capital
Over the past 11 years, 293 investors have co-invested in LYFE Capital's portfolio companies. This includes funds and angels.
- Invested before LYFE Capital: NLVC, Orbimed and 71 others have invested in rounds before LYFE Capital. There are 3 companies where NLVC has invested before LYFE Capital and 3 companies where Orbimed has invested before LYFE Capital.
- Top Co-investors of LYFE Capital: 115 investors entered a company along with LYFE Capital. These include investors like Hillhouse (4 companies).
- Invested after LYFE Capital: A total of 105 investors have invested in LYFE Capital's portfolio after their investments. Top Investors include CMB International Capital (3 companies), Greater Bay Area Homeland Investments (3 companies) and Loayal Valley Capital (3 companies).
Recent News related to LYFE Capital
•
Aspen’s $115M Series C Opens Doors to Late-Stage Development for Parkinson’s ProgramBioSpace•Nov 20, 2025•Aspen Neuroscience, Frazier Life Sciences, Revelation Partners, Orbimed and 10 others
•
•
Focusing on RNA drug development, Xingrui Pharmaceuticals completed over 300 million yuan in Series B financingPEdaily•Oct 24, 2025•LAV, Starna Therapeutics, Hillhouse, LYFE Capital and 3 others
•
Verdiva Bio joins weight loss race with $411M Series APitchBook•Jan 10, 2025•Verdiva Bio, Forbion, General Atlantic, Orbimed and 6 others
•
Verdiva Jumps Into Hot Obesity Market With $410M Debut, Eyes Next-Gen TherapiesBioSpace•Jan 09, 2025•Verdiva Bio, Forbion, General Atlantic, RA Capital Management and 4 others
•
UK-based Verdiva launches with $410m and an oral GLP-1RA candidatePharmaceutical Technology•Jan 09, 2025•Verdiva Bio, Forbion, General Atlantic, RA Capital Management and 4 others
•
CytoTronics Secures $13.5M Series Seed 2 Financing to Speed Market Entry of Pixel System for Breakthroughs in Cell BiologyBusiness Wire•Sep 05, 2024•CytoTronics, LYFE Capital, Anzu Partners, Legend Holdings and 4 others
•
Precision BioSciences Announces Proposed Public Offering of Common Stock and WarrantsBusiness Wire•Mar 01, 2024•Precision BioSciences, Guggenheim Securities, Perceptive Advisors, Janus Henderson Investors and 2 others
•
Capitalizing on ADC frenzy, ProfoundBio attracts $112M oversubscribed series BFierce Biotech•Feb 12, 2024•Profound Bio, LAV Asset Management, RA Capital Management, Orbimed and 12 others
•
Ysios Capital invests in Neurona Therapeutics' $120 million Series ECapital-Riesgo.es•Feb 09, 2024•Ysios Capital, Neurona Therapeutics, Viking Global Investors, Cormorant Asset Management and 15 others
